Advanced NanoTherapies Develops Innovative Dual-Drug Coated Balloon Platform for Vascular Treatments

Revolutionary Developments in Vascular Treatments

Introduction to Advanced NanoTherapies
Advanced NanoTherapies, Inc. (ANT) is poised to make significant strides in the realm of medical technology, focusing primarily on enhancing treatment outcomes for patients suffering from coronary and peripheral artery diseases. The company's latest innovation involves a pioneering platform featuring a drug-coated balloon (DCB) that utilizes a dual-drug delivery system, specifically incorporating sirolimus and paclitaxel, both well-established antiproliferative agents.

Funding Success and Future Goals
On June 2, 2026, ANT announced the successful closing of a Series B funding round, amassing over $31 million, which reflects a high demand for its innovative technology. This funding, co-led by an undisclosed strategic investor and S3 Ventures, aims to facilitate the approval of an Investigational Device Exemption (IDE) in the United States, alongside advancing clinical applications particularly targeting coronary arteries and below-the-knee applications.
Marwan Berrada-Sounni, CEO of ANT, stated, "This financial milestone arrives at a crucial moment for vascular intervention. While first-generation drug-coated balloons are gaining traction within the U.S. market, notable limitations regarding the passive administration of crystalline drugs remain evident. ANT's unique nanoparticle-based approach is necessary to propel advancements in local vascular therapy."

The SirPlux Duo Innovation
At the heart of this new endeavor is the SirPlux Duo. This dual-drug device is engineered to enhance cellular uptake within the vessel wall using a proprietary nanoparticle delivery system. By combining sirolimus and paclitaxel, ANT intends to overcome the limitations identified with existing treatments. Rishi Puri, an interventional cardiologist at the Cleveland Clinic, discusses the importance of this technology, emphasizing that it is engineered for sustained local drug retention at targeted sites with reduced dosages.
The goal of this innovative platform is to maximize therapeutic effects while promoting more predictable and durable vascular responses, presenting a significant upgrade from first-generation DCBs which utilize single crystalline drugs.

Regulatory and Clinical Advancements
Currently, ANT holds an exclusive license for this groundbreaking technology from the Cleveland Clinic. The SirPlux Duo is designed as a wholly biodegradable platform, aimed at future applications in coronary, peripheral, and broader vascular contexts. Notably, this project has received the designation of Innovative Therapy from the FDA, although commercial approval remains pending.
Azeem Latib, Medical Director of Structural Heart Intervention at Montefiore Einstein, noted, "The dual-drug delivery with controlled cellular uptake leads to enhanced potency at reduced doses, minimizing particle burden and maintaining future treatment options for vascular diseases."
Early clinical data supports this narrative, showcasing a human study involving 28 patients across Australia, the Dominican Republic, and New Zealand, which followed patients for two years without any therapeutic failure. Furthermore, research efforts in Spain are underway with another cohort of 30 patients to validate U.S. pivotal protocol outcomes.

Next Steps and Strategic Outlook
This substantial funding validates ANT’s robust platform and the momentum it has generated through scientific innovation and clinical execution. Brian R. Smith, CEO of S3 Ventures, remarked, "With clinical experience backed by two coronary studies and a clear regulatory path, ANT is well-positioned to further their key projects and deliver transformative therapies to patients in need of more effective options."
Looking ahead, ANT aims to ramp up production to meet FDA requirements for IDE applications in coronary and peripheral programs. Their priorities include addressing indications for intrastent re-stenosis and de novo lesions in small vessels, along with finalizing test packages for early feasibility studies.

Conclusion
As Advanced NanoTherapies embarks on this critical phase of development, its innovation in dual-drug coated balloon technology holds immense promise for the future of vascular treatment. With a commitment to enhancing patient care, ANT is set to make pivotal advancements that could reshape the landscape of interventional cardiology and beyond.